Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2)

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 4, 2010, Pages 714-721

  Eriksson, B I ^a   Turpie, A G G ^b   Lassen, M R ^c   Prins, M H ^d   Agnelli, G ^e   Kalebo P ^a   Wetherill, G ^f   Wilpshaar, J W ^f   Meems, L ^f  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b HAMILTON GENERAL HOSPITAL   (Canada)

^c Hoersholm Hospital   (Denmark)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e UNIVERSITY OF PERUGIA   (Italy)

^f Astellas Pharma Global Development   (Netherlands)

Author keywords

Direct factor Xa inhibitor; Oral anticoagulant; Prophylaxis; Total hip arthroplasty; Venous thromboembolism; YM150

Indexed keywords

ENOXAPARIN; YM 150;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLEEDING; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HUMAN; INCIDENCE; LEG PHLEBOGRAPHY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TOTAL HIP PROSTHESIS; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ARTHROPLASTY, REPLACEMENT, HIP; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENOXAPARIN; FACTOR XA; FIBRINOLYTIC AGENTS; HUMANS; INCIDENCE; LOGISTIC MODELS; MIDDLE AGED; PHLEBOGRAPHY; POSTOPERATIVE HEMORRHAGE; RISK ASSESSMENT; SURGICAL PROCEDURES, ELECTIVE; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 77649141852     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.03748.x     Document Type: Article

References (26)

1. Iwatsuki Y, Shigenaga T, Moritani Y, Suzuki M, Ishihara T, Hirayama F, Kawasaki T. Biochemical and pharmacological profiles of YM150, an oral direct factor Xa inhibitor. Blood 2006, 108:273A.
2. Saitoh M, Kaku S, Funatsu T, Koshio H, Ishihara T, Hirayama F, Kawasaki T, Sasamata M. Comparison of YM150, an oral, direct factor Xa inhibitor, with other antithrombotic agents in rodent venous and arterial thrombosis models. Blood 2007, 110:374A.
3. Eriksson BI, Turpie AGG, Lassen MR, Prins MH, Agnelli G, Kälebo P, Gaillard ML, Meems L. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost 2007, 5:1660-5.
4. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126:338S-400S.
5. Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972, 104:134-44.
6. Points to consider on multiplicity issues in clinical trials. 2002, 1-11. http://www.emea.europa.eu/pdfs/human/ewp/090899en.pdf, pp
7. Casella G. Refining binomial confidence intervals. Can J Stat 1986, 14:113-29.
8. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001, 358:9-15.
9. Eriksson BI, Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Kälebo P. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006, 4:121-8.
10. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, Rosencher N, Kälebo P, Panfilov S, Eskilson C, Andersson M, Freij A. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003, 1:2490-6.
11. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002, 359:1721-6.
12. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Buller HR. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007, 370:949-56.
13. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008, 358:2765-75.
14. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008, 358:2776-86.
15. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008, 372:31-9.
16. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Büller HR. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007, 5:2178-85.
17. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007, 5:2368-75.
18. Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kälebo P. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006, 114:2374-81.
19. Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Muehlhofer E, Kälebo P. Dose-escalation study of rivaroxaban (BAY 59-3739) - an oral, direct Factor Xa inhibitor - for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res 2007, 120:685-93.
20. European Medicines Agency Committee for Medicinal Products for Human Use. Recommendation on the need for revision of the guideline on clinical investigation of medicinal products for prophylaxis of intra- and posteoperative venous thromboembolic risk. 2007, 1-12. http://www.emea.europa.eu/pdfs/human/ewp/70798en_fin.pdf, pp
21. Norrie J. Trials of venous thromboembolism prevention. Lancet 2007, 370:915-7.
22. Turpie AG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kälebo P, Misselwitz F, Gent M. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005, 3:2479-86.
23. Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 2007, 116:180-7.
24. Carlson MK, Gleason PP, Sen S. Elevation of hepatic transaminases after enoxaparin use: case report and review of unfractionated and low-molecular-weight heparin-induced hepatotoxicity. Pharmacotherapy 2001, 21:108-13.
25. Boos CJ, Lip GY. Ximelagatran: an eulogy. Thromb Res 2006, 118:301-4.
26. http://www.emc.medicines.org.uk, SPC Clexane (enoxaparin), 4 April 2008 (Sanofi-Aventis)